Aduhelm: Case Study on Paying for Health by Paul Seegert
Insurance Thought Leadership - Nov 07, 2021
In July, I wrote an article that criticized the newly authorized Alzheimer’s drug Aduhelm. Six months later, the market response is heartening and, in my opinion, a case study in what it will take to fix the way that we pay for healthcare in America. A review of the problem The FDA approved the fi...
Recommended Articles
Posted: Apr 01, 2026
Telematics and Trust: The UBI Revolution Telematics ClareCarroll1 Wed, 04/01/2...
Posted: Apr 01, 2026
AI: Insurance Fraud Wake-Up Call Claims PaulCarroll Wed, 04/01/2026 - 10:17...
Posted: Mar 31, 2026
GenAI Takes Underwriting Into a New Phase Underwriting sradomski Tue, 03/31/20...